Caplin Point Lab

Why is Caplin Point Laboratories Ltd falling/rising?

As of 18-Aug, Caplin Point Laboratories Ltd's stock price is rising to 2,542.35, driven by strong financial performance and consistent gains over recent days. Despite a decline in delivery volume, the company's solid fundamentals and historical outperformance enhance investor confidence.

As of 18-Aug, Caplin Point Laboratories Ltd's stock price is rising, currently at 2,542.35, reflecting an increase of 21.8 points or 0.86%. This upward movement can be attributed to several factors. The stock has outperformed its sector by 0.88% today and has shown a consecutive gain over the last two days, with a total return of 2.49% during this period. <BR><BR>Additionally, the company has demonstrated strong financial performance, declaring positive results for the last 16 consecutive quarters, including record net sales of Rs 610.36 crore and a net profit after tax of Rs 176.91 crore in the latest quarter. The high management efficiency, indicated by a return on equity (ROE) of 19.33%, and the fact that the company is net-debt free further bolster investor confidence.<BR><BR>Despite a slight decline in investor participation, as evidenced by a 22.32% drop in delivery volume compared to the 5-day average, the stock remains liquid enough for trading. Furthermore, Caplin Point Laboratories has consistently generated significant returns over the past three years, outperforming the BSE500 in each of the last three annual periods. <BR><BR>Overall, these positive indicators contribute to the rising stock price of Caplin Point Laboratories Ltd.

Which are the latest news on Caplin Point Lab?

Should I buy, sell or hold Caplin Point Laboratories Ltd?

Who are in the management team of Caplin Point Lab?

The management team of Caplin Point Lab includes C C Paarthipan (Chairman), D Sathyanarayanan, C K Gariyali, Deenadayalan Singaram, and R Nagendran (all Independent Directors), along with Sridhar Ganesan (Non-Independent Executive Director).

The management team of Caplin Point Lab includes the following individuals:<BR><BR>1. C C Paarthipan - Chairman & Non-Executive Director<BR>2. D Sathyanarayanan - Independent Non-Executive Director<BR>3. C K Gariyali - Independent Director<BR>4. Deenadayalan Singaram - Independent Non-Executive Director<BR>5. R Nagendran - Independent Non-Executive Director<BR>6. Sridhar Ganesan - Non-Independent Executive Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Caplin Point Lab do?

Caplin Point Laboratories Ltd is a small-cap pharmaceutical company that develops, produces, and markets generic and branded products. As of June 2026, it reported net sales of ₹610 Cr and a net profit of ₹177 Cr.

Overview: <BR>Caplin Point Laboratories Ltd is a fully integrated pharmaceutical company engaged in the production, development, and marketing of a wide range of generic formulations and branded products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History: <BR>Incorporated on April 16th, 1990, Caplin Point Laboratories Ltd has maintained its status as a fully integrated pharma company. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 610 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 177 Cr (Quarterly Results - Jun 2026) <BR>Market cap: INR 18,813 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.28% <BR>Debt Equity: -0.28 <BR>Return on Equity: 17.88% <BR>Price to Book: 5.25 <BR><BR>Contact Details: <BR>Address: Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat Chennai Tamil Nadu : 600096 <BR>Tel: 91-44-24968000/71148000/28156653 <BR>Email: investor@caplinpoint.net/info@capli <BR>Website: http://www.caplinpoint.net

Who are the peers of the Caplin Point Lab?

Caplin Point Lab's peers include Acutaas Chemical, Pfizer, Granules India, Astrazeneca Phar, ERIS Lifescience, OneSource Specialty, Cohance Life, Alivus Life, and Alembic Pharma. Acutaas Chemical leads in 1-year return at 136.06%, while Caplin Point Lab has a return of 15.65%.

Peers: The peers of Caplin Point Lab are Acutaas Chemical, Pfizer, Granules India, Astrazeneca Phar, ERIS Lifescience, OneSource Speci., Cohance Life, Alivus Life, and Alembic Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Astrazeneca Phar, while Good management risk is found at Acutaas Chemical, Pfizer, Granules India, Caplin Point Lab, ERIS Lifescience, Alivus Life, and the rest. Average management risk is present at Cohance Life, and Below Average management risk is noted at OneSource Speci. Growth is Excellent at Acutaas Chemical and OneSource Speci., Average at Astrazeneca Phar, and Below Average at Pfizer, Granules India, Caplin Point Lab, ERIS Lifescience, Cohance Life, Alivus Life, and Alembic Pharma. Capital Structure is Excellent at Acutaas Chemical, Pfizer, Granules India, Astrazeneca Phar, Caplin Point Lab, Cohance Life, Alivus Life, and Alembic Pharma, while Good is seen at ERIS Lifescience and Below Average at OneSource Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Acutaas Chemical at 136.06%, while Cohance Life has the lowest at -54.93%. Caplin Point Lab's 1-year return of 15.65% is significantly higher than Cohance Life's but lower than Acutaas Chemical's. Additionally, ERIS Lifescience, OneSource Speci., and Cohance Life all have negative six-month returns.

How big is Caplin Point Lab?

As of 14th August, Caplin Point Laboratories Ltd has a market capitalization of 18,823.54 Cr, with recent net sales of 2,287.33 Cr and a net profit of 665.35 Cr.

As of 14th August, Caplin Point Laboratories Ltd has a market capitalization of 18,823.54 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,287.33 Cr and a Net Profit of 665.35 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,850.49 Cr and Total Assets of 3,205.62 Cr.

Has Caplin Point Laboratories Ltd declared dividend?

Yes, Caplin Point Laboratories Ltd has declared a dividend of 200%, amounting to ₹4 per share, with an ex-date of September 18, 2026. The company has demonstrated strong total returns across various periods, highlighting a positive outlook for investors.

Caplin Point Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4 per share<BR>- Ex-date: 18 Sep 26<BR><BR>Dividend Yield: 0.28%.<BR><BR>Total Returns by Period:<BR>In the 3 Months period, the price return was 23.0%, the dividend return was 0.40%, leading to a total return of 23.4%.<BR><BR>In the 6 Months period, the price return was 43.61%, the dividend return was 0.47%, resulting in a total return of 44.08%.<BR><BR>In the 1 Year period, the price return was 16.62%, the dividend return was 0.52%, culminating in a total return of 17.14%.<BR><BR>In the 2 Years period, the price return was 59.55%, the dividend return was 0.90%, which brought the total return to 60.45%.<BR><BR>In the 3 Years period, the price return was 145.6%, the dividend return was 2.00%, leading to a total return of 147.6%.<BR><BR>In the 4 Years period, the price return was 213.7%, the dividend return was 3.29%, resulting in a total return of 216.99%.<BR><BR>In the 5 Years period, the price return was 192.9%, the dividend return was 3.11%, culminating in a total return of 196.01%.<BR><BR>Overall, Caplin Point Laboratories Ltd has shown a strong performance with significant total returns across various periods, alongside a substantial dividend declaration, indicating a positive outlook for investors.

When is the next results date for Caplin Point Laboratories Ltd?

The next results date for Caplin Point Laboratories Ltd is 12 August 2026.

The next results date for Caplin Point Laboratories Ltd is scheduled for 12 August 2026.

Are Caplin Point Laboratories Ltd latest results good or bad?

Caplin Point Laboratories Ltd's latest Q4 FY26 results are generally positive, with a net profit of ₹170.11 crores and revenue of ₹600.16 crores, both showing significant year-on-year growth. However, a decline in operating margin raises some concerns, and while the market reacted favorably, investors should be cautious about potential margin pressures.

Caplin Point Laboratories Ltd's latest results for Q4 FY26 can be considered good overall. The company reported a net profit of ₹170.11 crores, which is a 3.80% increase quarter-on-quarter and a significant 19.32% increase year-on-year. Revenue also showed strong growth, reaching ₹600.16 crores, up 10.57% from the previous quarter and 19.45% compared to the same quarter last year.<BR><BR>However, there are some concerns regarding the operating margin, which declined to 34.03% from 34.95% in the previous quarter, indicating some pressure on operational efficiency. Despite this, the overall financial performance reflects a positive trend, with record highs in revenue and profit levels.<BR><BR>The market reacted positively to these results, with the stock price jumping nearly 10% following the announcement. While the company has strong fundamentals, the valuation appears stretched, and investors should remain cautious about potential margin pressures moving forward. Overall, the results indicate a strong financial trajectory, but ongoing monitoring of margin dynamics will be important.

Is Caplin Point Lab technically bullish or bearish?

As of November 27, 2025, Caplin Point Lab's technical trend has shifted to bearish, driven by negative indicators such as a bearish MACD and moving averages, despite some bullish signals in the monthly OBV.

As of 27 November 2025, the technical trend for Caplin Point Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. The Dow Theory also indicates a mildly bearish trend on the weekly and monthly time frames. Despite some bullish signals in the monthly OBV, the overall technical picture remains negative.

How has been the historical performance of Caplin Point Lab?

Caplin Point Lab has shown consistent growth, with net sales increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25, alongside improvements in operating profit, profit before tax, and total assets. Overall, the company's financial performance indicates a strong upward trend across key metrics.

Answer:<BR>The historical performance of Caplin Point Lab shows a consistent growth trajectory in key financial metrics over the years.<BR><BR>Breakdown:<BR>Caplin Point Lab has demonstrated significant growth in net sales, increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. The company's operating profit (PBDIT) has similarly improved, reaching 743.36 Cr in Mar'25, up from 250.37 Cr in Mar'19. Profit before tax has followed suit, climbing from 226.88 Cr in Mar'19 to 676.79 Cr in Mar'25, while profit after tax increased from 176.56 Cr to 541.10 Cr over the same period. The company's total assets have expanded from 1,125.76 Cr in Mar'20 to 3,205.62 Cr in Mar'25, indicating robust asset growth. Shareholder's funds have also risen significantly, from 947.91 Cr in Mar'20 to 2,850.49 Cr in Mar'25. Cash flow from operating activities has improved, reaching 432.00 Cr in Mar'25, compared to 44.00 Cr in Mar'20, while net cash inflow turned positive at 60.00 Cr in Mar'25 after a negative outflow in the previous year. Overall, Caplin Point Lab's financial performance reflects a strong upward trend across various metrics, indicating a healthy and growing business.

Is Caplin Point Lab overvalued or undervalued?

As of June 8, 2023, Caplin Point Lab is considered very expensive and overvalued with a PE ratio of 29.63 and an EV to EBITDA of 23.18, especially when compared to peers like Cipla and Sun Pharma, and has recently declined by 4.29% while the Sensex increased by 1.43%.

As of 8 June 2023, the valuation grade for Caplin Point Lab has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 29.63, an EV to EBITDA of 23.18, and a PEG ratio of 1.72, all suggesting a premium valuation compared to its earnings and growth potential.<BR><BR>In comparison with peers, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla presents a more attractive valuation with a PE of 22.99 and an EV to EBITDA of 15.93. The recent performance of Caplin Point Lab shows a 1-week decline of 4.29%, contrasting with a 1.43% increase in the Sensex, further reinforcing the notion of overvaluation in the current market environment.

Who are the top shareholders of the Caplin Point Lab?

The top shareholders of Caplin Point Lab include promoter P Vijayalakshmi with 24.71%, 17 mutual fund schemes holding 1.74%, 139 foreign institutional investors with 5.73%, and individual investors owning 15.11%. The highest public shareholder is Uti Small Cap Fund at 1.27%.

The top shareholders of Caplin Point Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is P Vijayalakshmi, who owns 24.71% of the company. Additionally, there are 17 mutual fund schemes that collectively hold 1.74%, and 139 foreign institutional investors (FIIs) with a combined holding of 5.73%. The highest public shareholder is Uti Small Cap Fund, which holds 1.27%. Individual investors also have a significant presence, holding 15.11% of the shares.